摘要
重组人干扰素α1b(rhIFN-α1b)是我国第一个国际独创的基因工程新药。在上一期中,已经概述了其作为人体天然抗病毒的主要干扰素亚型,具有高度的安全性和广谱抗病毒作用等特点,在儿科形成了符合我国国情的多个临床专家共识和指南。该文总结其在临床治疗儿科疾病的创新性研究和成果,并进一步探讨儿科临床应用rhIFN-α1b中需要研究解决的问题。
Recombinant human interferon α1b(rhIFN-α1b)is the first internationally unique novel genetic engineering medicine in China.In the previous article, it has been summarized that it is a major interferon subtype that is naturally antiviral in human body, and has high safety and broad-spectrum antiviral effect.A number of pediatric consensus and guidelines of clinical experts have formed in China′s national conditions.This article summarizes its innovative research and achievements in the clinical treatment of pediatric diseases, and further discusses the problems that need to be solved in the clinical application of rhIFN-α1b in pediatrics.
作者
张国成
尚云晓
Zhang Guocheng;Shang Yunxiao(Children's Hospital,Second Affiliated Hospital,Shanxi University of Chinese Medicine,Xi'an 710032,China;Shang Yunxiao Shengjing Hospital of China Medical University,Pediatric Respiratory Medicine,Shenyang 110004,China)
出处
《国际儿科学杂志》
2019年第8期541-544,共4页
International Journal of Pediatrics
关键词
干扰素Α1B
儿童
病毒
创新
Interferon α1b
Pediatrics
Virus
Innovation
